Medications That Can Cause Hyponatremia
Among the medications listed, Pristiq (desvenlafaxine), lisinopril, saxagliptin, and Rybelsus (semaglutide) can cause hyponatremia, while Jardiance (empagliflozin), glipizide, and Vraylar (cariprazine) have minimal to no established association with low sodium.
Medications with Established Hyponatremia Risk
Pristiq (Desvenlafaxine) - HIGH RISK
Pristiq carries significant hyponatremia risk as an SNRI antidepressant. SNRIs demonstrated the highest event rates for hyponatremia in geriatric populations (10.4% for any hyponatremia, 5.0% for clinically relevant hyponatremia), with a nearly 3-fold increased risk compared to non-users 1, 2. The mechanism involves syndrome of inappropriate antidiuretic hormone secretion (SIADH) 3. Monitor serum sodium particularly in:
- Elderly patients (mean age 80.5 years in emergency presentations) 4
- Those on polypharmacy (independent risk factor for 30-day revisits) 4
- First few weeks of therapy when risk is highest
Lisinopril - MODERATE RISK
ACE inhibitors like lisinopril can cause hyperkalemia but also contribute to hyponatremia through renin-angiotensin system effects. While guidelines primarily discuss hyperkalemia risk (8.4% in high-dose groups) 5, ACE inhibitors are recognized as hyponatremia-inducing agents in clinical practice 3. The risk increases when combined with:
- Diuretics (common in volume overload management) 6
- Heart failure patients
- Chronic kidney disease
Critical caveat: Medication review should include discontinuation of renin-angiotensin system inhibitors in patients with anasarca or volume overload 6.
Saxagliptin - LOW-MODERATE RISK
DPP-4 inhibitors including saxagliptin are generally well-tolerated but can contribute to hyponatremia. While guidelines note DPP-4 inhibitors are "generally well tolerated" 7, they have been identified in pharmacovigilance databases as hyponatremia-inducing drugs 3. The risk appears lower than with other diabetes medications but warrants monitoring, especially in:
- Older adults (≥65 years)
- Patients with moderate renal impairment
- Those on concurrent medications affecting sodium balance
Rybelsus (Semaglutide) - EMERGING RISK
Recent evidence suggests GLP-1 receptor agonists may cause hyponatremia, particularly when combined with diuretics. A 2026 case report documented recurrent symptomatic hyponatremia with tirzepatide (similar GLP-1 agonist) that resolved upon discontinuation 8. The FDA label for Rybelsus does not list hyponatremia as a primary adverse effect 9, but clinicians should:
- Monitor serum sodium when escalating doses
- Exercise particular caution with concurrent thiazide-like diuretics
- Consider the temporal association if hyponatremia develops
Medications with Minimal/No Hyponatremia Risk
Jardiance (Empagliflozin) - COMPLEX PROFILE
SGLT2 inhibitors like Jardiance have a paradoxical relationship with sodium. While they cause obligate increases in urine volume and can lead to volume depletion 7, they may actually improve sodium levels over time. In the DAPA-HF trial with dapagliflozin (similar SGLT2 inhibitor), more patients developed hyponatremia at day 14 (11.3% vs 9.4%), but by 12 months, fewer patients on the SGLT2 inhibitor had hyponatremia (4.6% vs 6.7%) 10. The primary concern is volume depletion, not hyponatremia per se.
Glipizide - MINIMAL RISK
Sulfonylureas like glipizide primarily cause hypoglycemia and weight gain, not hyponatremia 7, 11, 7. The FDA label emphasizes hypoglycemia risk but does not list hyponatremia 12. Guidelines recommend avoiding glyburide in older adults due to hypoglycemia risk, with glipizide being the preferred sulfonylurea as it lacks active metabolites 7, 11.
Vraylar (Cariprazine) - POSSIBLE BUT RARE
Antipsychotics as a class can cause hyponatremia, but evidence is limited. A systematic review found antipsychotic-induced hyponatremia occurs with both typical and atypical agents, often associated with polydipsia and SIADH 13. However, the causality was rated as "possible" in 80% of cases and "probable" in only 19% 13. Vraylar specifically lacks robust data linking it to hyponatremia.
Clinical Monitoring Algorithm
For patients on multiple medications from this list:
- Baseline sodium measurement before starting Pristiq, or when adding lisinopril to existing therapy
- Repeat sodium at 2 weeks after initiating/escalating Pristiq or Rybelsus
- Monthly monitoring for first 3 months in high-risk patients (age >65, polypharmacy, concurrent diuretics)
- Immediate evaluation if symptoms develop: confusion, falls, nausea, headache
Highest risk combinations: